Literature DB >> 33034720

Postoperative Adverse Events are Associated with Oncologic Recurrence Following Curative-intent Resection for Lung Cancer.

Stephen Gowing1, Laura Baker2, Alexandre Tran2, Zach Zhang3, Hilalion Ahn3, Jelena Ivanovic4,5, Caitlin Anstee1, Emma Grigor3, Sebastien Gilbert1, Donna E Maziak4,5,3,1, Farid Shamji1, Sudhir Sundaresan5,1, Patrick James Villeneuve1, Andrew J E Seely6,7,8,9.   

Abstract

BACKGROUND: Up to 50% of patients suffer short-term postoperative adverse events (AEs) and metastatic recurrence in the long-term following curative-intent lung cancer resection. The association between AEs, particularly infectious in nature, and disease recurrence is controversial. We sought to evaluate the association of postoperative AEs on risk of developing recurrence and recurrence-free survival (RFS) following curative-intent lung resection surgery.
METHODS: All lung cancer resections at a single institution (January 2008-July 2015) were included, with prospective collection of AEs using the Thoracic Morbidity & Mortality System. Cox proportional hazards models were used to estimate the effect of AEs on recurrence, with results presented as hazard ratio (HR) with 95% confidence interval (CI). An a priori, clinically driven approach to predictor variable selection was used. Kaplan-Meier curves were used examine the relationship between AE and RFS. p < 0.05 was considered statistically significant.
RESULTS: 892 patients underwent curative-intent resection. 342 (38.3%) patients experienced an AE; 69 (7.7%) patients developed infectious AEs. 17.6% (n = 157) of patients had disease recurrence after mean follow-up of 26.5 months. Severe (Grade IV) AEs were associated with increased risk of recurrence (3.40; 95% CI 1.56-7.41) and a trend to decreased RFS. Major infectious AEs were associated with increased risk of recurrence (HR 1.71; CI 1.05-2.8) and earlier time to recurrence (no infectious AE 66 months, minor infectious 41 months, major infectious 54 months; p = 0.02).
CONCLUSION: For patients undergoing curative-intent lung cancer resection, postoperative AEs associated with critical illness or major infection were associated with increased risk of oncologic recurrence.

Entities:  

Keywords:  Adverse events; Cancer recurrence; Infection; Lung cancer; Surgery

Year:  2020        PMID: 33034720     DOI: 10.1007/s00408-020-00395-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  30 in total

Review 1.  Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes.

Authors:  David Fedor; W Rainey Johnson; Sunil Singhal
Journal:  Surg Oncol       Date:  2013-05-20       Impact factor: 3.279

Review 2.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

3.  Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery.

Authors:  Eva Lieto; Gennaro Galizia; Annamaria Auricchio; Francesca Cardella; Andrea Mabilia; Nicoletta Basile; Giovanni Del Sorbo; Paolo Castellano; Ciro Romano; Michele Orditura; Vincenzo Napolitano
Journal:  J Gastrointest Surg       Date:  2017-07-27       Impact factor: 3.452

4.  The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a population-based survival analysis.

Authors:  Natasha M Rueth; Helen M Parsons; Elizabeth B Habermann; Shawn S Groth; Beth A Virnig; Todd M Tuttle; Rafael S Andrade; Michael A Maddaus; Jonathan D'Cunha
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

5.  Systematic classification of morbidity and mortality after thoracic surgery.

Authors:  Andrew J E Seely; Jelena Ivanovic; Jennifer Threader; Ahmed Al-Hussaini; Derar Al-Shehab; Tim Ramsay; Sebastian Gilbert; Donna E Maziak; Farid M Shamji; R Sudhir Sundaresan
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

Review 6.  Meta-analysis of the effect of postoperative in-hospital morbidity on long-term patient survival.

Authors:  P H Pucher; R Aggarwal; M Qurashi; A Darzi
Journal:  Br J Surg       Date:  2014-08-11       Impact factor: 6.939

Review 7.  Lung cancer.

Authors:  P C Hoffman; A M Mauer; E E Vokes
Journal:  Lancet       Date:  2000-02-05       Impact factor: 79.321

8.  A novel systematic inflammation related index is prognostic in curatively resected non-metastatic colorectal cancer.

Authors:  Tingting Hong; Di Shen; Xiaoping Chen; Dongyan Cai; Xiaohong Wu; Dong Hua
Journal:  Am J Surg       Date:  2017-07-19       Impact factor: 2.565

9.  The Society of Thoracic Surgeons Lung Cancer Resection Risk Model: Higher Quality Data and Superior Outcomes.

Authors:  Felix G Fernandez; Andrzej S Kosinski; William Burfeind; Bernard Park; Malcolm M DeCamp; Christopher Seder; Blair Marshall; Mitchell J Magee; Cameron D Wright; Benjamin D Kozower
Journal:  Ann Thorac Surg       Date:  2016-05-19       Impact factor: 4.330

10.  Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis.

Authors:  Jonathan Cools-Lartigue; Jonathan Spicer; Braedon McDonald; Stephen Gowing; Simon Chow; Betty Giannias; France Bourdeau; Paul Kubes; Lorenzo Ferri
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

View more
  3 in total

1.  The role of exosomal miR-181b in the crosstalk between NSCLC cells and tumor-associated macrophages.

Authors:  Junliang Ma; Shaolin Chen; Yingjie Liu; Hao Han; Ming Gong; Yongxiang Song
Journal:  Genes Genomics       Date:  2022-02-12       Impact factor: 2.164

2.  LUNG Year in Review: 2020.

Authors:  Peter V Dicpinigaitis
Journal:  Lung       Date:  2021-01-26       Impact factor: 2.584

3.  Long-Term Survival Impact of High-Grade Complications after Liver Resection for Hepatocellular Carcinoma: A Retrospective Single-Centre Cohort Study.

Authors:  Chin-Wen Kuo; Hsiang-Ling Wu; Chun-Cheng Li; Juan P Cata; Hsin-Yi Liu; Ming-Chih Hou; Yih-Giun Cherng; Ying-Hsuan Tai
Journal:  Medicina (Kaunas)       Date:  2022-04-12       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.